TABLE 1

Patient Characteristics

Patient no.	PSA (ng/mL)	Location of metastases	Previous pharmacotherapy	Previous radiotherapy	Previous radioactive drugs
1	227	LN, bone, liver, adrenal	Abi, Doce, Enza	RTx, bone	¹⁷⁷Lu (27.9 GBq)
2	239	Bone, LN, lung, skin	Keto, Estra, Doce, Abi, Trial, Enza	RTx, local and bone	⁹⁰Y (7.4 GBq)
3	697	LN, bone, adrenal	Abi, Doce, Trial, Cabazi	RTx, pelvic and bone	None
4	111	LN, bone	Abi, Enza, Doce	RTx, pelvic and bone	¹⁷⁷Lu (16 GBq)
5	481	Liver	Abi, Enza, Doce, Cabazi	RTx, local and pelvic	None
6	759	LN, bone	Abi, Enza, Doce, Cabazi	RTx, local, pelvic, and bone	¹⁷⁷Lu (44.4 GBq)
7	1,658	LN, bone	Abi, Doce, Cabazi, Estra, Enza	RTx, local and pelvic	None

PSA = prostate-specific antigene; LN = lymph node; Abi = abiraterone; Doce = docetaxel; Enza = enzalutamide; RTx = radiotherapy; Keto = ketoconazole; Estra = estramustine; Trial = Phase-1 trial of BAY2010112 (NCT01723475); Cabazi = cabazitaxel.